BMS to Cut 2,200 Jobs in $1.5B Restructuring as Opdivo Sales Drop in Q1 - BioSpace
Bristol Myers Squibb announced Thursday it is implementing major cost-cutting measures including thinning out its management layers. The pharma also reported modest revenue growth despite taking a 6% sales hit for lung cancer therapy Opdivo.| BioSpace
